CSL Behring Gets Indication For Acquired Factor XIII Deficiency For Fibrogammin P In Japan
This article was originally published in PharmAsia News
Executive Summary
CSL Behring on Sept. 13 obtained approval in Japan for the use of plasma derivative Fibrogammin P, the purified concentrate of blood coagulation factor XIII, for the treatment of bleeding caused by acquired factor XIII deficiency.
You may also be interested in...
Scotland's MGB Plots Phase III For Promising Antibacterial
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AstraZeneca Vaccine May Only Gain EU Approval In Under 70s
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.
Need a specific report? 1000+ reports available
Buy Reports